Post Hoc Data Show Daily Activity Participation, Independence And Sleep Quality Improved In Adults With Arthritis After Treatment With ORENCIA®

Bristol-Myers Squibb Company (NYSE: BMY) announced the results of three post-hoc analyses from two Phase III pivotal trials that showed ORENCIA® (abatacept) improved daily activity participation, such as work or household chores, physical and social-role independence and sleep quality in adul [click link for full article]

More: continued here

Filed under: Arthritis on November 18th, 2007